James Lillie
Vermögen: 3 Mio $ am 31.08.2026
Vermögen: 3 Mio $ am 31.08.2026
James Lillie is Chief Scientific Officer at MapLight Therapeutics, Inc. since 2019.
Formerly, Dr. Lillie was Senior Director-Biology at Scriptgen Pharmaceuticals, Inc. and Chief Scientific Officer at OvaScience, Inc. in 2018.
Dr. Lillie earned a doctorate from Harvard University and completed undergraduate studies at Wesleyan University.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 17.08.2026 | 210.110 ( 0,4 % ) | 3 Mio $ | 31.08.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| MAPLIGHT THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.02.2019 |
| Unternehmen | Position | Ende |
|---|---|---|
OvaScience, Inc.
OvaScience, Inc. Pharmaceuticals: MajorHealth Technology Engages in discovery, development and commercialization of new fertility treatment options for women | Technik-/Wissenschafts-/F&E-Leiter | 07.12.2018 |
Scriptgen Pharmaceuticals, Inc.
Scriptgen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops small molecule drugs | Corporate Officer/Principal | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 5 |
|---|---|
Scriptgen Pharmaceuticals, Inc.
Scriptgen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops small molecule drugs | Health Technology |
Harvard University
Harvard University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Wesleyan University
Wesleyan University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
OvaScience, Inc.
OvaScience, Inc. Pharmaceuticals: MajorHealth Technology Engages in discovery, development and commercialization of new fertility treatment options for women | Health Technology |
MapLight Therapeutics, Inc.
MapLight Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops therapeutics for debilitating central nervous system disorders | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen